Tasly Chuangshijie (Tianjin) Biological and Pharmaceutical Co., Ltd. announced that it will receive CNY 71,560,000 in its equity round of funding on December 2, 2016. The round will include participation from existing investors, Transgene SA (ENXTPA:TNG) and Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535), which will invest CNY 35,780,000, each to continue to hold 50% stake, each. Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535), will invest the whole amount in cash and Transgene SA (ENXTPA:TNG) will invest CNY 17,890,000 in cash and worth CNY 17,890,000 by its pox virus oncolytic carrier intellectual property.

The registered capital of the company will increase from CNY 85,000,000 to CNY 156,560,000 upon closing. The shares issued in this transaction will represent 45.707716% stake in the company, of which 22.853858% will be acquired by each of the investor. The transaction has been approved at 12th session of the 6th directorate of Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535).